Eli Lilly Raises Mounjaro Price in UK Amidst US Drug Price Pressure

Eli Lilly's Mounjaro Price Adjustment

• 📈 Eli Lilly, the top-performing stock in the S&P, is raising the list price of its diabetes drug Mounjaro in the UK.
• ⚠️ This move follows pressure from President Trump on big pharma to align US drug prices with international levels, a concept known as most favored nation status.

Strategic Pricing and Market Access

• 🎯 Dr. Kavita Patel suggests this price adjustment is part of a broader strategy by pharmaceutical companies to rebalance prices globally.
• 🤝 By adjusting UK and EU prices, companies may aim to secure a stronger position in negotiating demonstrations or programs related to Medicare in the US, their largest market.
• 🌐 It is anticipated that other pharmaceutical companies may follow suit with similar price adjustments.

Market Reaction and Novo Nordisk Comparison

• 📊 The market's reaction, including a nearly 4% rise in Eli Lilly's stock, is being analyzed, with some questioning if it's an overreaction.
• 💡 The recent Novo Nordisk news, while not entirely meeting expectations, was viewed positively by the clinical community for offering an oral option.
• 🚀 The current market momentum, potentially fueled by the obesity AI deal and positive clinical results, is contributing to the stock's performance.

Clinical Data and Future Outlook for Mounjaro

• 🔬 Dr. Patel will be closely examining the full readout of the oral drug data next month, focusing on discontinuation rates and side effects.
• 💊 The clinical community sees potential in oral options, especially if side effect profiles are incrementally lower than injectables like Mounjaro.
• 💰 While cost is a significant factor, it is not expected to be fully detailed in the upcoming readout, though anticipation is that oral drug costs may be lower than injectables due to supply chain efficiencies.